Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
調査の概要
状態
条件
詳細な説明
Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.
The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.
For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.
The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.
As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Boulogne Billancourt、フランス
- Hopital Ambroise Pare Ap-Hp
-
Brest、フランス
- Centre Hospitalier Universitaire Brest
-
Chambéry、フランス
- Centre Hospitalier Metropole Savoie
-
Créteil、フランス
- Centre Hospitalier Intercommunal de Créteil
-
Grenoble、フランス
- Centre Hospitalier Universitaire Grenoble Alpes
-
Le Chesnay、フランス
- Centre Hospitalier de Versailles André Mignot
-
Lille、フランス
- Centre Hospitalier Universitaire de Lille
-
Lyon、フランス
- Hospices Civils de Lyon
-
Lyon、フランス
- Centre Leon Berard Lyon
-
Mantes-la-Jolie、フランス
- Centre Hospitalier François Quesnay
-
Metz-Tessy、フランス、74374
- Centre Hospitalier Annecy Genevois
-
Paris、フランス
- Institut Curie
-
Saint-Cloud、フランス
- Institut Curie Saint Cloud
-
Saint-Étienne、フランス
- Institut de Cancérologie Lucien Neuwirth
-
Suresnes、フランス
- Hôpital Foch
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- At least 18 years old;
- Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
- Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
- Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
- Alive patients not opposed to the use of their data
Exclusion Criteria:
- Patient under guardianship or curatorship at the date of the study ;
- Patients alive at the time of the study who are opposed to the use of their data
- Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival
時間枠:Up to 12 months
|
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
|
Up to 12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Drugs administration dosage description
時間枠:Up to 12 months
|
Description of the different monthly drug administration regimens
|
Up to 12 months
|
|
Objective response rate and control rate
時間枠:Up to 12 months
|
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
|
Up to 12 months
|
|
Overall survival Rate
時間枠:Up to 12 months
|
Overall survival, assessed on the whole population
|
Up to 12 months
|
|
Objective Response Rate
時間枠:Up to 12 months
|
Objective Response Rate in the following subgroups:
|
Up to 12 months
|
|
Progression-Free Survival Rate
時間枠:Up to 12 months
|
Progression-Free Survival in the following subgroups:
|
Up to 12 months
|
|
Disease Control Rate
時間枠:Up to 12 months
|
Disease Control in the following subgroups:
|
Up to 12 months
|
|
Overall Survival Rate
時間枠:Up to 12 months
|
Overall Survival in the following subgroups:
|
Up to 12 months
|
|
Frequency of safety events
時間枠:Up to 12 months
|
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
|
Up to 12 months
|
協力者と研究者
捜査官
- 主任研究者:Chantal Decroisette、CH Annecy Genevois
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。